Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
14 angezeigte Treffer · Seite 1, keine Gesamtzahl für „mavacamten“
Suchtreffer
Begriffe & Kennungen
Camzyos · 4.5 · 10 Table 2: Dose modification/monitoring of mavacamten with concomitant medicinal products
Eintrag öffnenCamzyos · 4.5 · CYP2C19 inhibitors The effect of a moderate and strong CYP2C19 inhibitor on the PK of mavacamten was not inves
Eintrag öffnenCamzyos · 4.5 · CYP3A4 inhibitors The effect of strong CYP3A4 inhibitors on the PK of mavacamten was not investigated in a cli
Eintrag öffnenCamzyos · 4.5 · Discontinuing a moderate or weak inducer while on mavacamten treatment: Decrease mavacamten by one dose level
Eintrag öffnenCamzyos · 4.5 · Discontinuing or decreasing the dose of moderate or weak inducer while on mavacamten treatment: Decrease mavac
Eintrag öffnenCamzyos · 4.5 · Effect of mavacamten on other medicinal products Mavacamten in vitro data suggest a potential induction of CYP
Eintrag öffnenCamzyos · 4.5 · Effect of other medicinal products on mavacamten In CYP2C19 intermediate, normal, rapid and ultra-rapid metabo
Eintrag öffnenCamzyos · 4.5 · Strong CYP2C19 plus strong CYP3A4 inhibitors Co-administration of mavacamten with the combination of a strong
Eintrag öffnenCamzyos · 4.8 · Adverse reactions reported in patients treated with mavacamten in two phase 3 studies (EXPLORER- HCM and VALOR
Eintrag öffnenCamzyos · 4.8 · Dyspnoea In Phase 3 clinical studies, dyspnoea was reported in 12.3% of patients treated with mavacamten compa
Eintrag öffnenCamzyos · 4.8 · Systolic dysfunction In Phase 3 clinical studies, 5% (9/179) of patients in the mavacamten group experienced r
Eintrag öffnenCamzyos · 4.8 · The most commonly reported adverse reactions with mavacamten are dizziness (17%), dyspnoea (12%), systolic dys
Eintrag öffnenMavacamten
Eintrag öffnenmavacamten
Eintrag öffnen